argenx SE (0QW0.L)
| Previous close | 82.30 |
| Open | 107.10 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 105.00 - 107.10 |
| 52-week range | 105.00 - 107.10 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 4.005B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.37 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
argenx Highlights Strategic Priorities for 2022
BREDA, Netherlands, January 07, 2022--argenx Highlights Strategic Priorities for 2022
- Globe Newswire
argenx to Present at 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 7:30 a.m. ET. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay o
- Business Wire
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
BREDA, Netherlands, December 17, 2021--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211217005641/en/
